8-K current report · filed Jun 25, 2026

Bio-Techne (TECH) 8-K Current Report: June 25, 2026

Item 7.01Item 5.02Item EX-99.1TECH overview

Short answer

Bio-Techne (TECH) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Disclosure references Bio-Techne’s February 11, 2026 Form 8-K covering officer and director matters.

Bio-Techne 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Disclosure references Bio-Techne’s February 11, 2026 Form 8-K covering officer and director matters
  • Director and executive ownership changes reflected through SEC Forms 3 and 4
  • Future proxy materials expected to detail transaction participants and their interests

Item 7.01 · Regulation FD Disclosure

  • Proposed Merck KGaA acquisition of Bio-Techne remains subject to shareholder approval and other closing conditions
  • Transaction introduces closing risk from competing offers, regulatory delays, litigation, integration challenges and financing impacts
  • Bio-Techne plans to file a Schedule 14A proxy statement with transaction details for shareholder review
  • Proposed deal could disrupt operations, employee retention and customer relationships before or after closing

Item EX-99.1 · Exhibit EX-99.1

  • Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, valuing the transaction at approximately $11.3 billion
  • Offer represents a 36% premium to Bio-Techne’s one-month volume-weighted average trading price, creating near-term cash value for shareholders
  • Closing targeted for late 2026 or early 2027, subject to shareholder approval and regulatory clearances
  • Merck expects approximately €140 million in annual cost synergies, fully realized by year 3 after closing
  • Bio-Techne generated more than $1.2 billion in fiscal 2025 sales and brings multi-omics, spatial biology, diagnostics, and cell-therapy capabilities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bio-Techne 8-K filings

Get the next TECH 8-K as it lands

Follow TECH for push alerts, or ask the research agent what this filing means.